- GE HealthCare Technologies Inc. (NASDAQ:GEHC) experienced a 13% stock drop to a new 52-week low after lowering its full-year 2026 profit guidance, despite a history of exceeding earnings expectations.
- Amid the market downturn, CFO Saccaro James demonstrated investor confidence by purchasing 3,310 shares at $60.60, significantly increasing his personal investment in the company.
- While Q1 2026 revenue of $5.13 billion surpassed estimates, adjusted earnings per share (EPS) of $0.99 missed the Zacks Consensus Estimate, leading to a revised 2026 adjusted EPS guidance of $4.80 to $5.00 due to persistent supply chain pressures and rising operational costs.
GE HealthCare Technologies Inc. (NASDAQ:GEHC) is a medical technology company that was spun off from General Electric. It specializes in medical imaging, diagnostics, and patient monitoring solutions, with annual revenues of approximately $20.60 billion. The company faces ongoing challenges from supply chain issues and rising costs.
Recently, GEHC stock experienced a sharp decline, dropping 13% in one day to a new 52-week low of $58.75. This drop occurred after the company reduced its profit guidance for the full year 2026. The revision broke a streak of several quarters where GEHC had exceeded earnings expectations, as highlighted by 247wallst.com.
Amid this downturn, Chief Financial Officer Saccaro James demonstrated confidence by purchasing 3,310 shares on May 1, 2026. He bought the shares at a price of $60.60 each. This transaction increased his total ownership in the company to 87,471 shares, representing a significant personal investment following the stock’s price drop.
The negative market reaction was tied to GEHC’s first-quarter 2026 results. While revenue grew 7.4% to $5.13 billion, beating estimates, its adjusted earnings per share (EPS) of $0.99 fell short of the Zacks Consensus Estimate of $1.07. EPS is a company’s profit divided by its outstanding shares, indicating profitability for shareholders.
Looking ahead, GEHC has lowered its full-year 2026 adjusted EPS guidance to a new range of $4.80 to $5.00. As reported by Proactive Investors, the company also reduced its adjusted EBIT margin forecast. Management attributes this revised outlook to persistent supply chain pressures and increased operational costs.
